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ABSTRACT 
Title 
Estimation of total and free phenytoin concentration in low albumin patients 
admitted in critical care 
 
Background  
Phenytoin has been widely used in the prophylaxis and treatment of epilepsy. 
However, dosing phenytoin is challenging because it exhibits non linear 
pharmacokinetics, zero order elimination and a multitude of drug interactions. 
Phenytoin is also highly protein bound (90%). It is the unbound or free form 
which can cross the blood brain barrier and causes both the therapeutic and toxic 
effects. A fall in serum albumin concentration can alter phenytoin binding 
capacity. In this situation, estimating total phenytoin concentration which 
includes the bound and unbound portions will provide discrepant results 
compared to the actual free phenytoin concentration. 
 
Aim 
  To compare free phenytoin concentration measured by three methods 
(Direct serum measurement, Routine method and by the Sheiner Tozer 
calculation method). 
 To estimate total phenytoin concentration by two method (Direct serum 
measurement and Sheiner Tozer calculated total method) and if feasible, to 
develop a model to predict the free measured phenytoin concentration from total 
phenytoin concentration. 
 
Methods:  
 
This was an observational study. Patients in the Medical Intensive Care Unit who 
were on phenytoin, were observed from the day of admission. When serum 
albumin level was <3.5 g/dL, blood samples were collected prior to phenytoin 
administration in patients. Direct measurement of total and free phenytoin 
concentration was done by High Performance Liquid Chromatography. Free 
phenytoin was also estimated by the Sheiner Tozer equation and routine method 
(Direct measured total/10). 
 
Results: 
 
The total and free phenytoin concentration was measured in 57 patients with low 
albumin.  The median and interquartile range for direct measured total and 
Sheiner Tozer calculated total phenytoin concentration was 9.82(6.02-13.85) and 
17.14(10.63-24.53) respectively. There was a mean relative difference of 42% in 
the total phenytoin direct measured concentration compared to the Sheiner Tozer 
calculated total phenytoin. Seventy five % of patients if reported only using the 
direct measured concentration would have total phenytoin concentration within 
the therapeutic range, whereas these patients would be supratherapeutic by the 
Sheiner Tozer calculation. These patients would require a reduction in the 
phenytoin dose, which would be unlikely if the clinician’s judgement is based 
ONLY on the direct measured total phenytoin. 
 
 The median (IQR) for routine, direct measured and Sheiner Tozer free phenytoin 
was 0.98 (0.60 - 1.39), 1.92 (1.06 -2.76) and 1.71 (1.06 - 2.45) respectively. The 
correlation coefficient (r
2
) for direct measured with routine free phenytoin and 
with Sheiner Tozer calculated free concentrations was found to be 0.63 and 0.64 
respectively.  And if the phenytoin concentration was reported using the Sheiner 
Tozer calculated total, 33% of patients would be falsely reported as therapeutic 
whilst being supratherapeutic in the direct measured free method. 
 
Conclusion: 
 
Our study concluded that the total phenytoin concentration based on the Sheiner 
Tozer corrected equation is different from the direct measured concentration by 
High Performance Liquid Chromatography, in patients with low albumin. In 
addition, free phenytoin concentration can only be reported from a direct 
measured value and not any prediction/equation. 
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